Global Quality Assurance and Regulatory Compliance: The Business Case for an Enterprise-Wide Strategy - A centralized quality control strategy may be the best solution. - BioPharm International

ADVERTISEMENT

Global Quality Assurance and Regulatory Compliance: The Business Case for an Enterprise-Wide Strategy
A centralized quality control strategy may be the best solution.


BioPharm International
Volume 21, Issue 11


Denise Queffelec
For the biopharmaceutical industry, product quality and regulatory compliance are fundamentals of business operations and profitability. In recent years, the industry has become increasingly global. Factors contributing to this globalization include dispersed physical manufacturing locations, the reliance on outside partners such as contract manufacturing organizations (CMOs), and the use of multiple active pharmaceutical ingredient (API) suppliers. As the biopharmaceutical manufacturing industry becomes increasingly global, it faces new quality and compliance challenges.

Many biopharmaceutical companies maintain decentralized, global networks of virtually independent plants with the following: varying operational and management processes; diverse monitoring and reporting systems; dissimilar equipment or infrastructure; and multiple local or regional suppliers, contractors, and vendors. However, these companies recognize that, just as their sales and distribution programs have evolved to meet global opportunities, their quality assurance and regulatory compliance programs must change.

With ultimate responsibility for assuring the quality and compliance of their products, sponsoring companies must manage a complex web of assets in an ever-changing regulatory framework. Biopharmaceutical companies are confronted with a growing list of requirements imposed by organizations such as the European Medicines Agency (EMEA), and the US Food and Drug Administration (FDA). The US, the European Union, and Japan have an ongoing goal of creating a harmonized regulatory compliance standard, and the International Conference on Harmonization (ICH) has produced its Q8, Q9, and Q10 guidelines to address quality assurance and risk management issues. Meanwhile, in the US, two FDA programs—Pharmaceutical cGMPs (current good manufacturing practices) for the 21st Century, and the Pharmaceutical Quality Assessment Pilot—both of which focus on risk-based analysis, remain works in progress. The FDA is also revising its cGMP regulations, and it intends to publish the revisions this year.

Some biopharmaceutical companies have already turned away from the traditional methodology of assigning quality and compliance responsibilities to individual facilities or partners, because this approach often produces inconsistent results. These companies have embraced a new, enterprise-wide strategy for quality assurance and regulatory compliance. This strategy helps achieve quality and compliance goals and creates a competitive advantage.

BEST PRACTICES FOR INTEGRATED QUALITY AND COMPLIANCE


The Return on Investment (ROI) of Best Practices
Companies pioneering enterprise-wide quality and compliance initiatives maintain a series of best practices anchored by centralized quality-management controls. Returns on investment arise not only from product quality and regulatory compliance, but also from optimized resources and profitability. Company experiences, combined with the observations and knowledge of industry experts, provide a blueprint for implementing best practices in achieving a global GMP compliance program based on quality. Key elements of that blueprint include: consistent messaging and common nomenclature, certifications of employees and subcontractors, enterprise-wide training, centralized documentation and distribution, vendor certification, integrated systems management, and quality systems inspection approach.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here